SNX16 and colorectal carcinoma: The results of the Kaplan–Meier survival analysis suggested that patients with high SNX16 expression levels (P = 0.019) had adverse clinical outcomes among 232 CRC patients from the GEO database (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17538; Fig. 1F), especially in stage III (P = 0.048) or IV (P = 0.007) patients with CRC but not in stage I (P = 0.938) or II (P = 0.569) patients (Fig. 1G–J).